Breast Cancer Department, Division for Medical Oncology, University Hospital for Tumors, Sestre Milosrdnice UCC, Zagreb, Croatia.
Department of Clinical Oncology, Santa Casa Misericordia Porto Alegre, Porto Alegre, Brazil; Post-Graduation Program in Pathology, Federal University of Health Sciences of Porto Alegre (UFCSPA), Brazil.
Breast. 2022 Oct;65:67-76. doi: 10.1016/j.breast.2022.06.007. Epub 2022 Jul 7.
Standard chemotherapy for early breast cancer consists generally of an anthracycline - taxane - based regimen, preferably in sequence. Anthracyclines are among the most active cytotoxic drugs against breast cancer. Nevertheless, benefits attained by the use of the more potent anthracycline schedules must be balanced against increased short - and long - term toxicity, and treatment options must be individualized for each patient. Authors review available data regarding anthracycline efficacy and toxicity in the early breast cancer setting and the potential directions for future research.
早期乳腺癌的标准化疗通常包括蒽环类药物-紫杉类药物为基础的方案，最好是序贯治疗。蒽环类药物是乳腺癌最有效的细胞毒性药物之一。然而，使用更强效的蒽环类方案所获得的益处必须与增加的短期和长期毒性相平衡，并且必须为每个患者个体化治疗选择。作者回顾了早期乳腺癌中蒽环类药物疗效和毒性的现有数据，以及未来研究的潜在方向。
